As it continues efforts to best allocate cash to its network of businesses amid a decline in earnings, the Fresenius SE & Co. KGaA group has defined Fresenius Kabi AG as a “top priority.” Meanwhile, Fresenius has stressed, it is likely to remain Kabi’s sole owner, as it disclosed a willingness to hive off equity stakes in its other businesses.
Fresenius Puts Kabi At The Top As It Ponders Best Use Of Cash
‘Assume We Will Remain Sole Kabi Owner’ Under Potential Investments
The Fresenius group has all but ruled out any equity investment in Fresenius Kabi, as it looks to make the best use of its capital and “tap new capital sources” to drive growth.
More from Strategy
More from Business
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.